Physician profile
Mohsin Rupani
NPI 1750048187
$1,750.95
in general payments reported to CMS, 2019-2025
16 companies · $762 in 2025
The $762 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.77 · 2023: $499 · 2024: $470 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.24 |
| Education | $166.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $648.01 | 2024-2025 | |
| Incyte Corporation | $199.87 | 2023-2025 | Jakafi, Niktimvo |
| Astellas Pharma US INC | $190.39 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $170.61 | 2023-2025 | |
| Legend Biotech USA INC. | $110.10 | 2023-2025 | Carvykti |
| Servier Pharmaceuticals LLC | $105.33 | 2023 | |
| Genentech USA, INC. | $78.89 | 2024-2025 | Columvi, Venclexta, Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $56.80 | 2023-2025 | Livtencity |
| Sanofi-Aventis U.S. LLC | $39.92 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $27.49 | 2024 | Ultomiris |
| Autolus INC | $27.09 | 2025 | |
| Jazz Pharmaceuticals INC. | $23.16 | 2024 | |
| Stemline Therapeutics INC. | $20.06 | 2025 | Elzonris |
| Lundbeck LLC | $19.93 | 2024 | Vyepti |
| Optinose US, INC. | $19.77 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $13.53 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsin Rupani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.